The US Food and Drug Administration’s change of mind on the preferred COVID-19 vaccine formulation for 2024-2025 means there will be at least one JN.1 variant-targeted vaccine on the market come fall despite the agency’s new recommendation for a KP.2 subvariant formulation.
On 13 June, the agency announced it had advised manufacturers to use the KP.2 strain of the JN.1-lineage virus “if...






